Phase 3 Study Shows BI Bevacizumab Biosimilar Comparable to Reference Product

January 19, 2022

Two biosimilars, Pfizer’s Zirabev and Amgen’s Mvasi, have been approved for indications including unresectable, locally advanced NSCLC and recurrent or metastatic nonsquamous NSCLC. BI 695502 is no longer under development by Boehringer Ingelheim.

Industry Group Representative Discusses Biosimilars in Michigan

January 19, 2022

Real-world Study Sees Adoption of Mvasi by US Oncologists for Metastatic CRC

January 18, 2022

Pharmacokinetic and Pharmacodynamic Equivalence of Biocon’s Proposed Biosimilar Insulin-R to Humulin-R

January 17, 2022

Wayne Winegarden, PhD, Discusses Which Insurance Type He Expects Will Have the Greatest Biosimilar Savings

January 16, 2022

International Biosimilars Trade Group Appoints New Leadership for 2022

January 15th 2022

By Tony Hagen

Article

The International Generic and Biosimilar Medicines Association has appointed a veteran member, Vivian Frittelli, MBA, ACIS, to take over as chair.

The Top 5 Biosimilar Articles for the Week of January 10

January 14th 2022

By Skylar Jeremias

Video

Here are the top 5 biosimilar articles for the week of January 10, 2022.

Michigan Trade Group Outlines Best Practices for Biosimilar Adoption

January 13th 2022

By Tony Hagen

Article

Ford Motor saved $5 million by switching patients to 5 biosimilars, and other manufacturers and employers in Michigan have achieved good results with switching programs, the Economic Alliance of Michigan reports.

Robert Popovian, PharmD, MS, Discusses Biosimilar Progress and Education in the United States

January 12th 2022

By Tony Hagen

Video

As chief science policy officer for Global Healthy Living Foundation, Robert Popovian, PharmD, MS, has a bird’s-eye view of some of the central issues of biosimilar access in the United States.

Amgen CEO Touts Potential for Doubling in Biosimilar Revenue

January 11th 2022

By Tony Hagen

Article

Amgen Chairman and CEO Robert Bradway touted the potential of 11 biosimilars anticipated to be driving revenues for the company by 2030.

Developers Advised to Challenge Regulatory Standards to Speed Development of Biosimilars

January 11th 2022

By Meir Rinde, MS

Article

In a recent paper, Sarfaraz K. Niazi, PhD summarizes some of his central ideas on the relevance of FDA biosimilar testing standards.

Canada Clears Alvotech Adalimumab Biosimilar for Launch

January 10th 2022

By Tony Hagen

Article

Simlandi (AVT02) is the second high-concentration, citrate-free adalimumab (Humira) biosimilar to be approved in the Canada market.

Wayne Winegarden, PhD, Discusses His Predictions for Etanercept, Adalimumab Biosimilar Pricing Discounts

January 9th 2022

By Skylar Jeremias

Video

Wayne Winegarden, PhD, a senior fellow in business and economics at Pacific Research Institute, discusses his predictions for etanercept and adalimumab biosimilar pricing and why he hopes manufacturers will offer them at large discounts to reference biologics.

In India, Patient Advocates Lobby for Modernized Biosimilar Development Standards

January 8th 2022

By Tony Hagen

Article

In India, an emphasis on outdated biosimilar testing has restricted market entry of these products and discouraged manufacturers, patient advocates contend.

The Top 5 Biosimilar Articles for the Week of January 3

January 7th 2022

By Skylar Jeremias

Video

Here are the top 5 biosimilar articles for the week of January 3, 2022.